

# Cystic Fibrosis

## Dyslipidemia in Brazilian Children

Araujo, ACMF<sup>1</sup>; Monte, LFV<sup>2</sup>; Moreira, CR<sup>2</sup>; Abdalla, A<sup>3</sup>; Bezerra, ACA<sup>4</sup>

1- Resident of Pediatric Endocrinology of Hospital de Base do Distrito Federal | 2- Pediatric Pulmonology of Hospital de Base do Distrito Federal and Hospital da Criança de Brasília  
3- Graduate student of Medicine of Universidade Católica de Brasília | 4- Pediatric Endocrinology of Hospital de Base do Distrito Federal and Hospital da Criança de Brasília

### BACKGROUND

Cystic fibrosis (CF) is an inherited disease of the secretory glands. The CF is an autosomal recessive genetic disorder that affects most critically the lungs, and also the pancreas, liver and intestine.<sup>1</sup> It is characterized by abnormal transport of chloride and sodium across an epithelium, leading to thick, viscous secretions.<sup>2</sup>

The CF gene codes for the CFTR (cystic fibrosis transmembrane regulator) protein, which is 1,480 amino acids. The most prevalent mutation of CFTR is the deletion of a single phenylalanine residue at amino acid 508 ( $\Delta F508$ ). Cystic fibrosis occurs most frequently in Caucasians of northern European descent, in whom the CF gene is most common — although people of other heritages can have the disease, too.<sup>1,2,3</sup>

The life expectancy of these patients are increasing and new complications have been observed, among them are the repercussions on the endocrine system, such as changes in carbohydrate metabolism, lipid metabolism, bone metabolism, pubertal development, impaired growth and disease thyroid.

### OBJECTIVES AND HYPOTHESIS

Cystic fibrosis is associated with abnormal lipid metabolism and this abnormality is commonly characterized by low cholesterol and hypertriglyceridemia. The increase in life expectancy of cystic fibrosis patients has been enhancing the interest to prevent the risk factors for cardiovascular diseases like dyslipidemias<sup>5,6,7</sup>. Hyperlipidemia is common in the general population and is associated with significant morbidity and mortality.<sup>5,8,9</sup>

The aim of this study is to determine whether concentrations of cholesterol and triacylglycerol are related to nutritional status and fasting glucose in pediatric patients with cystic fibrosis.

### METHOD

This is a cross sectional study by record review of patients with cystic Fibrosis treated in the pediatric pulmonology department at Hospital da Criança de Brasília. Sixty four patients were selected for our study and 52 patients had information on lipid profile for the last 6 months. Patients without such medical records were excluded from the study. Fasting lipid profiles and fasting glucose were measured in 52 pediatric patients with cystic fibrosis (10,5 ± 5,0y - 23F/29M). Data were analyzed with the use of Sigma Stat 3.5 and are presented as means ± SDs.

### RESULTS

Twenty patients (38,4%) presented hypertriglyceridemia (143,437,8mg/dL), and 9 patients (17,3%) hypercholesterolemia (16215mg/dL). In most cases, hypertriglyceridemia was isolated; only 3 subjects had elevation of both cholesterol and hypertriglyceridemia. Twenty-eight patients (53,8%) had low HDL-cholesterol (34,86,5mg/dL).

Table 1 – Results of CF patients of Hospital da Criança de Brasília

	CF population (23F/29M)
Age (y)	10,5 ± 5,0
Triacylglycerol (mg/dL)	20 (38,4%) 143,4 ± 37,8mg/dL
Cholesterol (mg/dL)	9 (17,3%) 162 ± 15mg/dL
HDL Cholesterol (mg/dL)	28 (53,8%) 34,8 ± 6,5mg/dL

Fourty patients (76,9%) were healthy weight (normal range), six patients were overweight (11,5%), four (7,6%) underweight and one was obesity and another severe underweight (table 2).

In this study, four patients (7,6%) presented altered carbohydrate metabolism: altered oral glucose tolerance test (OGTT) and elevated A1C test measure.

Table 2 – Results of body mass index in CF patients of Hospital da Criança de Brasília

BMI (Zscore) <sup>WHO</sup>	CF population (23F/29M)
Underweight ( $\geq z-3$ e $< z-2$ )	-0,99 ± 2,8
Healthy weight (normal range) ( $\geq z-2$ e $< z+1$ )	+0,44 ± 0,77
Overweight ( $\geq z+1$ e $< z+2$ )	+1,45 ± 0,28

Lipid concentrations were not related to body mass index, gender or age or fasting glucose (table 3).

Table 3 – Correlation between lipid profile and fasting glucose and the Z score of BMI

CF population (n=52)	Zscore BMI
Cholesterol (mg/dL)	0,143 (p=0,316)
HDL Cholesterol (mg/dL)	-0,537 (p<0,001)
Triglycerides (mg/dL)	0,252 (p=0,0739)
Fasting glucose (mg/dL)	0,0493 (p=0,740)

Table 4 – Correlation between lipid profile and gender

CF population (n=52)	Total Cholesterol (TC)	Triglycerides (TG)
Female (n=23)	128,00 ± 24,03	90,27 ± 55,66
Male (n=29)	120,35 ± 24,13	95,86 ± 44,48
	1,124 (p=0,266)	-0,399 (p=0,692)

These results have shown a group with higher triacylglycerol, lower cholesterol and lower HDL-cholesterol concentrations than the general Brazilian pediatric population. There is a study of lipid profile among schoolchildren in Brazil that

Table 5 – Comparison between CF group and Pediatrics Brazilian average<sup>12</sup>

	Cholesterol (mg/dL)	HDL Cholesterol (mg/dL)	Triglycerides (mg/dL)
CF Group	162±15	34,8±6,5	143,4±37,8
Mean for Pediatrics Brazilian population <sup>12</sup>	160±30	49±12	79±39

corroborates these results, which is shown in table 3.

It is speculated that hypertriglyceridemia in CF may be related to inflammation. CF patients experience chronic inflammation exacerbated by frequent bouts of acute infection.<sup>5</sup> Pro-inflammatory cytokines such as tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) are known to be mediators of hyperlipidemia in infection and in severe stress because they both inhibit lipoprotein lipase activity (thereby decreasing triacylglycerol clearance) and stimulate hepatic lipogenesis.

Table 6 – Lipid profile references in population under 20 years old - V Brazilian Guideline for Dyslipidemia and Prevention of Atherosclerosis of BSC - 2013.<sup>16</sup>

	Desirable (mg/dL)	Borderline (mg/dL)	High (mg/dL)
TC	< 150	150-169	$\geq 170$
LDL-C	< 100	100-129	$\geq 130$
HDL-C	$\geq 45$		
TG	< 100	100-129	$\geq 130$

\*BSC: Brazilian Society of Cardiology; TC: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; e TG: triglycerides.

Fasting hypertriglyceridemia can occur in individuals who chronically consume a high-carbohydrate, low-fat diet.<sup>15</sup>

### CONCLUSION

Isolated hypertriglyceridemia appears to be common in cystic fibrosis, whereas cholesterol concentrations are generally low. Abnormal lipid metabolism is associated with a high risk of cardiovascular disease in the general population, like elevation in cholesterol and triacylglycerol and low HDL-cholesterol, these findings arouse an importance to understand the abnormalities in lipid metabolism in this special group of children with cystic fibrosis in order to prevent the risk factors of cardiovascular diseases and to improve their survival. We speculate that the hypertriglyceridemia was related to chronic, low-grade inflammation. Alternatively, dietary fat malabsorption, together with enhanced glucose absorption from the gut, may lead to hypertriglyceridemia as is seen in individuals who consume high-carbohydrate, low-fat diets. Dietary absorption and lipid turnover studies will be needed to further explore these hypotheses.

### REFERENCES

- NELSON. Textbook of pediatrics. — 19th ed. / [edited by] Robert M. Kliegman ... [et al.]. Elsevier. 2011.
- MANNA, T.D.; SETIAN, N.; RODRIGUES, J.C. O diabetes melito na fibrose cística: uma comorbidade cada vez mais frequente. Arquivo Brasileiro Endocrinologia e Metabologia. São Paulo, v.52, n.2, Mar. 2008. Disponível em: <http://dx.doi.org/10.1590/S0004-27302008000200006>. Acesso em: 05 Nov 2013.
- Reis FJC, Damasceno N. Fibrose Cística. J Pediatr 1998; 74 (Supl 2):76-94.
- Dodge JA, Lewis PA, Stanton M, Wilsher J. CF mortality and survival in the UK: 1947–2003. Eur Respir J 2007;29:522–6.
- Figuerola V, Milla C, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal lipid levels in cystic fibrosis. Am J Clin Nutr 75:1005–1011, 2002.
- Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350:560–569.
- Alves CAD, Lima DS. Cystic fibrosis-related dyslipidemia. J Bras Pneumol. 2008;34:829–837.
- Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. Best Pract Res Clin Gastroenterol. 2006;20(3):531–46.
- Sociedade Brasileira de Cardiologia. I Diretriz de prevenção da aterosclerose na infância e na adolescência. Arq Bras Cardiol. 2005;85(Suppl 6):S1–S36.
- I. Hammana, L. Coderre, S. Potvin, M. Costa, Y. Berthiaume, A. Lavoie et al. Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study. J Cyst Fibros. 8 (2) (Mar 2009), pp. 128–134.
- Alves C, Veiga S, Souza T. Dislipidemia e risco de doença cardiovascular em crianças e adolescentes com diabetes melito tipo 1. Rev Paul Pediatr. 2007; 25(1):82-9.
- Moura EC, Clésio MC, Aparecida SM e Dalcélia BF. Perfil lipídico em escolares de Campinas, SP, Brasil Rev. Saúde Pública, 34 (5): 499-05, 2000.
- Lepage G, Paradis K, Lacaille F, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with CF. J Pediatr 1997;130:52–8.
- Burdge GC, Goodale AJ, Hill CM, Halford PJ, Lambert EJ, Postle AD, et al. Plasma lipid concentrations in children with cystic fibrosis: the value of a high-fat diet and pancreatic supplementation. Br J Nutr. 1994;71(6):959-64.
- Parks EP, Hellerstein MK. Carbohydrate-induced hypertriglyceridemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000;71:412–33.
- XAVIER, H. T. et al. V Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose. Arq. Bras. Cardiol., São Paulo, v. 101, n. 4, supl. 1, Oct. 2013. Available from <http://www.scielo.br/scielo.php?script=sci\_arttext&pid=S0066-782X2013004100001&lng=en&nrm=iso>. access on 05 Aug. 2014. http://dx.doi.org/10.5935/abc.2013S010.